Blog
RSS FeedPosted by Michael Wonder on 18 Jul 2019
Toddler died of only meningococcal strain not on vaccine program
18 July 2019 - A toddler has died after contracting meningococcal B, the only strain of the potentially deadly disease with ...
Posted by Michael Wonder on 18 Jul 2019
LifeMax receives rare paediatric disease designation for LM-030 for the treatment of Netherton syndrome
18 July 2019 - LifeMax Laboratories today announced that the FDA granted rare paediatric disease designation to LM-030, an investigational therapy ...
Posted by Michael Wonder on 17 Jul 2019
Perth boy battles cystic fibrosis, with a life extending drug frustratingly out of reach
15 July 2019 - In many ways Connor Barrett is just like any other kid - he loves Peppa Pig ...
Posted by Michael Wonder on 17 Jul 2019
LogicBio Therapeutics receives rare paediatric disease designation for LB-001 for the treatment of methylmalonic acidaemia
16 July 2019 - LogicBio Therapeutics today announced the U.S. FDA has granted rare paediatric disease designation to LB-001, a ...
Posted by Michael Wonder on 11 Jul 2019
Health Canada has authorised Vyvanse (lisdexamphetamine dimesylate), the first and only, chewable tablet for the treatment of attention deficit/hyperactivity disorder
10 July 2019 - Vyvanse offers an additional option for patients who prefer the convenience of a chewable tablet, or who ...
Posted by Michael Wonder on 10 Jul 2019
FDA approves Katerzia, the first and only amlodipine oral suspension for paediatric patients 6 years of age and older
10 July 2019 - Azurity Pharmaceuticals announced today that the U.S. FDA has approved Katerzia (amlodipine) 1 mg/mL oral suspension, ...
Posted by Michael Wonder on 08 Jul 2019
Family to stay in Australia after son with cystic fibrosis initially deemed a 'burden'
8 July 2019 - A Victorian family at risk of being deported back to their homeland of Ireland after their ...
Posted by Michael Wonder on 01 Jul 2019
New treatment for children with type 2 diabetes mellitus
28 June 2019 - EMA’s CHMP has recommended granting an extension of indication to Victoza (liraglutide) to include the treatment of ...
Posted by Michael Wonder on 22 Jun 2019
FDA approves Botox (onabotulinumtoxinA) for paediatric patients with upper limb spasticity
21 June 2019 - Approval marks 10th Botox therapeutic indication in its 30th anniversary year. ...
Posted by Michael Wonder on 21 Jun 2019
FDA expands approval of treatment for cystic fibrosis to include patients ages 6 and older
21 June 2019 - The U.S. FDA today expanded the indication for Symdeko (a combination of tezacaftor/ivacaftor) tablets for treatment of ...
Posted by Michael Wonder on 17 Jun 2019
FDA approves new treatment for paediatric patients with type 2 diabetes
17 June 2019 - The U.S. Food and Drug Administration today approved Victoza (liraglutide) injection for treatment of paediatric patients 10 ...
Posted by Michael Wonder on 13 Jun 2019
FDA grants priority review to Genentech’s Rituxan (rituximab) in children with two rare blood vessel disorders
12 June 2019 - If approved, this would be the first paediatric indication for Rituxan. ...
Posted by Michael Wonder on 12 Jun 2019
Ford government to fund Spinraza, world’s most expensive drug - with age caps
12 June 2019 - The Ford government today announced it will be covering the cost of the drug Spinraza for ...
Posted by Michael Wonder on 08 Jun 2019
PTC Therapeutics receives FDA approval for the expansion of the Emflaza (deflazacort) labeling to include patients 2-5 years of age
7 June 2019 - Emflaza is the only approved treatment for all patients two and over living with Duchenne muscular dystrophy. ...
Posted by Michael Wonder on 05 Jun 2019
Rotorua toddler faces being 'trapped in his own body', parents plead for Spinraza drug funding
5 June 2019 - The last time the Rotorua Daily Post spoke to Rotorua mum Anna Sutherland, her son Heath ...